Cornell Nanoparticles Cure Cancer in 40% of Trial Mice

Scientists just discovered that microscopic particles made from silicon dioxide can do something remarkable: destroy cancer tumors while teaching the immune system to fight back.

Researchers at Weill Cornell Medicine and Cornell Engineering tested their ultrasmall nanoparticles on mice with aggressive prostate cancer. The results surprised even the scientists themselves. When combined with existing immunotherapy treatments, the particles led to complete remissions in 40% of the mice, with tumors disappearing entirely and never coming back.

The particles, called Cornell Prime dots or C' dots, work in two powerful ways at once. First, they trigger a self-destruct process in cancer cells called ferroptosis, where the tumor cells essentially oxidize themselves to death. Second, they flip a switch in the immune system, transforming "cold" tumors that hide from immune cells into "hot" ones that the body can actively attack.

What makes this especially promising is what didn't happen. The particles caused zero toxicity in healthy tissues. Even organs like the spleen, where the particles briefly concentrated, showed no signs of damage.

Dr. Michelle Bradbury, who led the study published in Cancer Research, calls it a potential new clinical paradigm. The nanoparticles pick up iron ions from the bloodstream and deliver them directly into tumor cells, where they catalyze the runaway oxidation that destroys cancer membranes. Meanwhile, immune cells that were previously inactive or even helping the tumor suddenly switch to attack mode.

The material itself comes from silicon dioxide, the same compound found in healthy foods like leafy greens and cereal grains. Professor Ulrich Wiesner wonders if this ancient connection between silica and biology explains why it works so selectively, targeting only cancer while leaving healthy cells untouched.

The Ripple Effect

This discovery could unlock immunotherapy's potential in prostate cancer, where lasting responses have been frustratingly difficult to achieve. The particles were originally designed just for medical imaging, but their therapeutic effects emerged through years of research. They're already in advanced clinical trials for other applications, meaning the path to human testing could be shorter than usual.

Dr. Jedd Wolchok, director of the Parker Institute for Cancer Immunotherapy at Weill Cornell Medicine, notes that combining direct tumor killing with immune system activation creates conditions for more effective responses. The treatment doesn't just attack the cancer once; it trains the body to keep fighting.

Four mice with aggressive cancer are now living tumor-free indefinitely, something researchers say no other treatment has achieved with such durability.

Human trials are the next frontier for these remarkable particles that turn cancer's hiding places into battlegrounds where the immune system can finally win.